March 10, 2026

Tirzepatide outperforms semaglutide for weight loss

Real-world data show greater weight loss with dual incretin therapy.

The New Gastroenterologist

January 22, 2026

GLP-1 therapy in Crohn's disease: Fewer steroids, hospitalizations

“What stood out most was the consistent association between GLP-1 receptor agonist use and lower steroid dependence."

The New Gastroenterologist